Content deleted Content added
VertyBerty (talk | contribs) |
VertyBerty (talk | contribs) |
||
Line 22:
AAA currently has a total of 31 sites in 12 countries, including: 19 production facilities in 8 countries (in Europe and the U.S.) that manufacture targeted radioligand therapies and precision imaging radioligands, and 6 sites with R&D activity.
In October 2017, Novartis announced that it intended to acquire the company for US$3.9 billion.<ref>{{Cite web |last=Wirtschaftswoche |title=Advanced Accelerator Applications: Novartis kauft Krebsspezialisten für 3,9 Milliarden Dollar |url=https://www.wiwo.de/unternehmen/industrie/advanced-accelerator-applications-novartis-kauft-krebsspezialisten-fuer-3-9-milliarden-dollar/20520264.html |access-date=2022-08-20 |website=www.wiwo.de |language=de}}</ref>
==Products==
| |||